Keeping Current

Is it time to rethink perioperative immunotherapy in resectable gastric and gastroesophageal junction (GEJ) cancers? See the latest data and expert takeaways.   Credit available for this activity expires: 7/18/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002710?ecd=bdc_podcast_libsyn_mscpedu